News related to Uroxatral (Alfuzosin) and/or conditions it is approved for
Benign Prostatic Hyperplasia
Source: MedicineNet Prostatitis Specialty [2008.06.23]
Title: Benign Prostatic Hyperplasia
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 6/23/2008
Medical and Surgical Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: State of the Art
Source: Medscape Pharmacotherapy Headlines [2004.06.11]
Read clinically focused news coverage of key developments from the meeting.
Medscape Medical News
Claus Roehrborn
Nymox Reports Positive New Results In 59 Week Study Of Drug For Enlarged Prostate
Source: Prostate / Prostate Cancer News From Medical News Today [2008.11.17]
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce positive new results from the Company's most recent study of NX-1207, its drug in development for benign prostatic hyperplasia (BPH). A total of 67 patients and controls in this multi-center U.S. study consisting of 92% of eligible patients were followed for an average of 59 weeks after a single administration of NX-1207. Of the patients given full dose NX-1207, 76.7% required no further treatment compared to 37.
Herb Studied For Enlarged Prostate - Saw Palmetto Therapeutic For Urinary Symptoms?
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2008.11.07]
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older. The research team, led by Dr. Steven A.
|
